1. 149OEfficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies. (25th November 2018) Authors: Kang, Y-K; Kudo, M; Lim, H-Y; Hsu, C-H; Vogel, A; Brandi, G; Cheng, R; Carton, I; Abada, P; Hsu, Y; Zhu, A; Yen, C-J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 210TiPIMbrave150: A randomised phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. (25th November 2018) Authors: Qin, S; Cheng, A-L; Ducreux, M P; Galle, P R; Zhu, A; Kim, T-Y; Xu, D-Z; Verret, W; Liu, J; Finn, R S; Ikeda, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Dendrobine attenuates isoniazid- and rifampicin-induced liver injury by inhibiting miR-295-5p. (December 2020) Authors: Ci, R; Zhang, K; Zhu, A; Zang, W Journal: Human & experimental toxicology Issue: Volume 39:Number 12(2020) Page Start: 1671 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. LBA-001Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH). (24th June 2018) Authors: Zhu, A; Finn, R; Galle, P; Llovet, J; Blanc, J F; Okusaka, T; Chau, I; Abada, P; Hsu, Y; Kudo, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). (24th November 2019) Authors: Cheng, A-L; Qin, S; Ikeda, M; Galle, P; Ducreux, M; Zhu, A; Kim, T-Y; Kudo, M; Breder, V; Merle, P; Kaseb, A; Li, D; Verret, W; Xu, Z; Hernandez, S; Liu, J; Huang, C; Mulla, S; Lim, H Y; Finn, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Nickel oxide nanoparticles induced pulmonary fibrosis via TGF-β1 activation in rats. (August 2017) Authors: Chang, XH; Zhu, A; Liu, FF; Zou, LY; Su, L; Liu, SK; Zhou, HH; Sun, YY; Han, AJ; Sun, YF; Li, S; Li, J; Sun, YB Journal: Human & experimental toxicology Issue: Volume 36:Number 8(2017) Page Start: 802 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. (20th June 2018) Authors: Meric-Bernstam, F; Arkenau, H; Tran, B; Bahleda, R; Kelley, R; Hierro, C; Ahn, D; Zhu, A; Javle, M; Winkler, R; He, H; Huang, J; Goyal, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. (20th June 2018) Authors: Meric-Bernstam, F; Arkenau, H; Tran, B; Bahleda, R; Kelley, R; Hierro, C; Ahn, D; Zhu, A; Javle, M; Winkler, R; He, H; Huang, J; Goyal, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. O-008Proof of concept of the abscopal effect in MSS GI cancers: A phase 2 study of ipilimumab and nivolumab with radiation in metastatic pancreatic and colorectal adenocarcinoma. (2nd July 2019) Authors: Parikh, A; Clark, J; Wo, J; Yeap, B; Allen, J; Blaszkowsky, L; Ryan, D; Giantonio, B; Weekes, C; Zhu, A; Seventer, E Van; Ly, L; Matlack, L; Foreman, B; Drapek, L; Ting, D; Corcoran, R; Hong, T Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. O-021Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). (2nd July 2019) Authors: Meyer, T; Finn, R; Kudo, M; Kang, Y; Yen, C; Galle, P; Llovet, J; Assenat, E; Brandi, G; Motomura, K; Okusaka, T; Hubner, R; Karwal, M; Baron, A; Ikeda, M; Liang, K; Wang, C; Widau, R; Schelman, W; Zhu, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗